Lobe Sciences Ltd.

CNSX: LOBE


Canadian symbol: LOBE.CN
US symbol: GTSIF

Currency in CAD

Valuation Measures

Market Cap (intraday) 520.97M
Enterprise Value 321.06M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)23.60
Price/Book (mrq)1.40
Enterprise Value/Revenue 323.70
Enterprise Value/EBITDA 7-5.59

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3157.14%
S&P500 52-Week Change 343.61%
52 Week High 30.2700
52 Week Low 30.0300
50-Day Moving Average 30.1394
200-Day Moving Average 30.1276

Share Statistics

Avg Vol (3 month) 3994.16k
Avg Vol (10 day) 3942.39k
Shares Outstanding 5199.73M
Implied Shares Outstanding 6N/A
Float 179.65M
% Held by Insiders 111.24%
% Held by Institutions 12.66%
Shares Short (Apr. 14, 2021) 4468.99k
Short Ratio (Apr. 14, 2021) 41
Short % of Float (Apr. 14, 2021) 4N/A
Short % of Shares Outstanding (Apr. 14, 2021) 40.23%
Shares Short (prior month Mar. 14, 2021) 4114.75k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Aug. 30, 2020
Most Recent Quarter (mrq)Nov. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-438.92%

Management Effectiveness

Return on Assets (ttm)-24.78%
Return on Equity (ttm)-43.63%

Income Statement

Revenue (ttm)888.53k
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)2.10%
Gross Profit (ttm)841.56k
EBITDA -3.77M
Net Income Avi to Common (ttm)-4M
Diluted EPS (ttm)-0.0430
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)165.96k
Total Cash Per Share (mrq)0
Total Debt (mrq)256.86k
Total Debt/Equity (mrq)2.06
Current Ratio (mrq)3.42
Book Value Per Share (mrq)0.08

Cash Flow Statement

Operating Cash Flow (ttm)-2.45M
Levered Free Cash Flow (ttm)-1.24M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LOBE.CN
Lobe Sciences
1 week ago
LOBE.CN
Lobe Sciences
1 week ago
LOBE.CN
Lobe Sciences
5 months ago
LOBE.CN
Lobe Sciences
5 months ago
LOBE.CN
Lobe Sciences
11 months ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
11.24%% of Shares Held by All Insider
2.66%% of Shares Held by Institutions
2.99%% of Float Held by Institutions
1Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Lobe Sciences Ltd.


Lobe Sciences Announces Changes to Board of Directors

Appointment of Michael Petter to the Board brings another seasoned board member with strong industry, capital markets and strategic planning expertise.Vancouver, British Columbia--(Newsfile Corp. - January 8, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Mi... Read More...

Lobe Sciences Announces Further Upsizing and Second Closing of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce, that due to strong investor demand, it has further upsized its previously announced non-brokered private placement of units (the "Units") from $2,700,000 to $3,445,847 (the "O... Read More...

Lobe Sciences Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it intends to raise up to Cdn$2,000,000 (the "Offering") through a non-brokered private placement of up to 20,000,000 units (the "Units") at a price of Cdn$0.10 per Unit... Read More...

Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors

Appointment of Jonathan Gilbert as Executive Chairman allows Lobe to capitalize on his significant capital markets experienceVancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that the appointment of Mr. Jonathan Gilbert as E... Read More...

Lobe Sciences Commences Engineering of Nasal Mist Device

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device.This is a ... Read More...

Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.

Signed LOI for CAD$23 million sale to Ionic provides shareholder valueVancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has received and signed a non-binding letter of intent dated November 30, 2020 with IONIC Brands ... Read More...

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine ("NAC") for the treatment of mild traumatic brain injury/concussion ("mTBI") with post-trauma... Read More...

Lobe Sciences Commences Trading Under New Name and Announces Rebranding and Corporate Update

Lobe Sciences unveils new corporate name and logo as part of an extensive rebranding initiative, reflective of the Company's focus on psychedelic medicinesVancouver, British Columbia--(Newsfile Corp. - November 16, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that today it will ... Read More...

GreenStar Biosciences Announces Name Change

Vancouver, British Columbia--(Newsfile Corp. - November 11, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") announces today it will be seeking approval of the Canadian Securities Exchange (the "CSE") to change its name from GreenStar Biosciences Corp. to Lobe Sciences Ltd. and change its CS... Read More...

GreenStar Biosciences Completes Acquisition of 100% of Eleusian Biosciences Corp. and Appoints Jonathan Gilbert to Board of Directors and Maghsoud Dariani as Chief Science Officer

Strategic acquisition by GreenStar adds innovative company focused on the development of effective therapeutics using psychedelic medicineVancouver, British Columbia--(Newsfile Corp. - July 27, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") is pleased to announce, further to its press rele... Read More...

GreenStar Biosciences Signs Definitive Agreement to Acquire 100% of Eleusian Biosciences Corp.

Strategic acquisition by GreenStar to add innovative company focused on the development of effective therapeutics using psychedelic medicineVancouver, British Columbia--(Newsfile Corp. - July 21, 2020) -  GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") is pleased to announce, further to its press r... Read More...

GreenStar Biosciences Announces New CEO and Board Changes

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company"), is pleased to announce the appointment of Mr. Thomas Baird as Chief Executive Officer and director of the Company. Mr. Baird's appointment is a key step in furthering GreenStar's nex... Read More...

Greenstar Biosciences Announces Grant of Stock Options

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2020) -  GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company"), announces it has granted stock options to acquire a total of 1,900,000 common shares of the Company to certain officers, directors and consultants of the Company. The options are exe... Read More...

Greenstar Biosciences Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2019) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company"), announces that it attended the recent MJBizCon cannabis investment conference to held in Las Vegas, Nevada. MJBizCon is the premier cannabis investment conference with over 35,000 at... Read More...

GreenStar Biosciences Comments on Market Activity

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2019) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar"), at the request of the Investment Industry Regulatory Organization of Canada (IIROC), has issued this press release to confirm that the Company's management is not aware of any material undisclosed de... Read More...

Greenstar Biosciences Announces M&A Focussed Strategic Additions to Its Executive Team and Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - December 6, 2019) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company"), announces that it has engaged Invictus Accounting Group LLP ("Invictus") to provide CFO and strategic advisory services to the Company.Mr. Brian Zasitko has been appointed the Company... Read More...

Greenstar Biosciences Achieves OTC Listing

Vancouver, British Columbia--(Newsfile Corp. - October 10, 2019) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") is pleased to announce the Company has been approved for trading its common shares on the OTC Pink market, a US trading platform that is operated by the OTC Markets Group in New York. ... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
LOBE.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed0.09CAD--
6YX.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.06EUR-12.00%
GTSIF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.09USD+19.86%
GTSIF.PQ
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.09USD+21.24%

Delayed data (1h)
NameAgePositionAppointed
Ralph Olson
President
--President2019
Thomas W. Baird
Chief Executive Officer, Director
55Chief Executive Officer, Director2020
Gavin Cooper
Chief Financial Officer, Director
73Chief Financial Officer, Director2015
Emily Davis
Director
--Director2017
Vince Sorace
Director
--Director2019


Share this page